# Possession, Not Just Promise: Ariad v. Eli Lilly and the Separate Written-Description Requirement

> The en banc Federal Circuit confirmed that Section 112 demands a written description separate from enablement, invalidating Ariad's NF-kB patent for claiming a result it never showed it possessed.

Topic: Patents  |  Author: Lidiia Levitska  |  Source: Intellectual Property Law (outsideipcounsel.com)
Canonical: https://outsideipcounsel.com/blog/ariad-v-eli-lilly-separate-written-description-requirement/


When the en banc Federal Circuit handed down *Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co.*, 598 F.3d 1336 (Fed. Cir. 2010) (en banc), it settled a question that had divided patent lawyers for years: does 35 U.S.C. Section 112, first paragraph, contain a written-description requirement that stands apart from the requirement of enablement? Writing for the court, Judge Alan Lourie answered yes. A patent specification must not only teach a skilled person how to make and use the invention; it must also demonstrate that the inventor actually possessed the claimed subject matter when the application was filed. On that ground the court affirmed the invalidation of patent claims that, in the court's view, described a hoped-for result rather than the means of achieving it.

## At a glance

- **Case:** *Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co.*, 598 F.3d 1336 (Fed. Cir. 2010) (en banc); originating from the U.S. District Court for the District of Massachusetts.
- **Court:** U.S. Court of Appeals for the Federal Circuit, sitting en banc; opinion by Judge Lourie for the court, with concurrences and a partial dissent (Judges Rader and Linn would have read Section 112 to require only enablement).
- **Posture:** En banc rehearing of a panel decision, after a jury found infringement of U.S. Patent No. 6,410,516 and the claims survived initial validity challenges; the question was whether the claims met the written-description requirement.
- **Holding:** Section 112, first paragraph, contains a written-description requirement separate from and in addition to enablement; the asserted Ariad claims were invalid for failing it.
- **Significance:** Cemented "possession" as the touchstone of patent disclosure and constrained broad functional and genus claims, especially in the life sciences.

The patent at issue grew out of pioneering work on NF-kB, a transcription factor that switches on genes involved in the body's response to infection and inflammation. The inventors, from Harvard, MIT, and the Whitehead Institute, theorized that reducing NF-kB activity could treat a range of diseases. Ariad, the exclusive licensee, sued Eli Lilly after two of Lilly's drugs were alleged to work through that pathway. The trouble was the scope of what Ariad had claimed.

## A claim to a result, not a molecule

The asserted claims were strikingly broad. They covered methods of reducing NF-kB activity in cells, regardless of which molecule or mechanism accomplished the reduction. In effect, Ariad claimed the goal — turn down NF-kB to treat disease — rather than any particular drug, compound, or class of compounds that would reach it. The specification gestured at three broad categories of potential molecules (decoy molecules, dominantly interfering molecules, and specific inhibitors) but offered little in the way of working examples that actually achieved the claimed result.

The en banc court found this fatal. A patentee who claims a genus, it explained, must disclose either a representative number of species falling within that genus or structural features common to the members so that a skilled artisan can recognize what is claimed. Ariad had done neither. It had described research plans and hypotheses, not invention. As the court put it, the law does not reward "an invitation for further research." The hard work of identifying molecules that actually reduce NF-kB activity remained to be done; claiming the result before doing that work overreached.

## Reading the statute: "describe" and "enable" as two duties

Much of the opinion is statutory interpretation. Section 112, first paragraph, requires that the specification contain "a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable" a skilled person to make and use it. The dissenters read that single sentence as imposing one requirement — enablement — with "written description of the invention" merely identifying what must be enabled.

Judge Lourie's majority parsed the grammar differently. The phrase "a written description of the invention" stands as its own object, separate from "the manner and process of making and using it." Two distinct things must be described; only the latter is governed by the enablement clause. The court reinforced this reading with history, pointing to long-standing precedent — including *Regents of the University of California v. Eli Lilly & Co.* — that had policed claims for adequate description independent of enablement. The en banc court declared that line of cases good law.

## The possession standard and its limits

Having confirmed the requirement, the court described how to apply it. The test is whether the disclosure reasonably conveys to those skilled in the art that the inventor "had possession of the claimed subject matter as of the filing date." Possession is shown in the four corners of the specification, judged from the perspective of a person of ordinary skill. It is a question of fact, sensitive to the technology and the breadth of the claims.

The court was careful to say it was not imposing a heightened standard unique to biotechnology, though it acknowledged the doctrine has outsized effects there. Functional claiming — defining an invention by what it does rather than what it is — remains permissible, but only where the specification ties the function to enough structure that a skilled reader can see the inventor truly had the full scope in hand. The newer the field and the more unpredictable the art, the more disclosure the requirement demands.

## Open questions

- **How many species are "representative"?** The court declined to set a number, leaving the sufficiency of genus disclosures to case-by-case, fact-intensive judgment.
- **Where is the line between possession and an invitation to research?** Early-stage discoveries of a mechanism, with promising but incomplete chemistry, will continue to test that boundary.
- **How heavily does unpredictability weigh?** The opinion ties the quantum of required disclosure to the predictability of the art, but how much extra description an unpredictable field demands remains contested.

## Implications

- **Claim what you have shown.** Disclosure must demonstrate possession of the full claimed scope; aspirational or result-defined claims invite invalidity.
- **Genus claims need species or structure.** To claim a class of compounds, disclose representative members or common structural features tying the genus together.
- **Two hurdles, not one.** A specification can enable yet still fail written description, and vice versa; patent drafters must clear both bars under Section 112.
- **Functional claiming is risky.** Defining an invention by the result it achieves is permissible only when structure is disclosed to support the function across the claim's breadth.
- **File when the science is mature.** Premature applications that capture a goal before the inventive work is done are especially vulnerable.

## Frequently asked questions

**What is the difference between written description and enablement?**
Written description asks whether the specification shows the inventor actually possessed the claimed invention as of the filing date. Enablement asks whether the specification teaches a skilled person how to make and use it. After *Ariad*, both are independent requirements under Section 112, and a claim can satisfy one but fail the other.

**Why did Ariad's patent fail?**
The asserted claims covered any substance that reduces NF-kB activity to treat disease, but the specification described the desired result rather than the specific molecules that achieve it. The en banc court found the patent disclosed only research goals and hypotheses, not a representative number of species or common structural features, so it did not show possession of the broad genus claimed.

**Does Ariad change the law for everyone or just for biotech?**
The holding applies to all fields, but it bites hardest where claims are functional or define a genus, common in biotech and chemistry. There the specification must disclose representative species or shared structural features, not just a function the invention is supposed to perform.

## Authorities and sources

- Federal Circuit en banc opinion (No. 2008-1248, official PDF): https://www.cafc.uscourts.gov/opinions-orders/08-1248.pdf
- CourtListener opinion page, *Ariad Pharm. v. Eli Lilly*, 598 F.3d 1336: https://www.courtlistener.com/opinion/599/ariad-pharmaceuticals-inc-v-eli-lilly-and-co/
- 35 U.S.C. Section 112 (Cornell Legal Information Institute): https://www.law.cornell.edu/uscode/text/35/112
- Finnegan analysis, "Ariad v. Lilly: Written Description Requirement Separate from Enablement": https://www.finnegan.com/en/insights/articles/ariad-v-lilly-written-description-requirement-separate-from.html